KC
M. Kyle Cromer
University of California, San Francisco, Stanford University, Yale University, Virginia Tech, Harvard Medical School
Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · CRISPR and Genetic Engineering · Virus-based gene therapy research · CAR-T cell therapy research
0000-0002-8198-5010
Employment
-
University of California, San Francisco Associate Professor2026 - Present
-
University of California, San Francisco Assistant Professor2022 - 2026
-
Stanford University Instructor2020 - 2022
-
Stanford University Postdoc2016 - 2020
-
Harvard Medical School Postdoc2014 - 2016
Education
-
Yale University PhD2009 - 2014
-
Yale University MPhil2009 - 2012
- 2005 - 2009
Projects & Funding
Projects & funding information is unavailable.
Publications (21)
- Protocol for efficient CRISPR/AAV-mediated genome editing and erythroid differentiation of human hematopoietic stem and progenitor cells Save
- Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis Save
- Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells Save
- Engineering inducible signaling receptors to enable erythropoietin-free erythropoiesis Save
- Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells Save
- Using human genetics to develop strategies to increase erythropoietic output from genome-edited hematopoietic stem and progenitor cells Save
- Transient Inhibition of 53BP1 Increases the Frequency of Targeted Integration in Human Hematopoietic Stem and Progenitor Cells Save
- CRISPR nuclease off-target activity and mitigation strategies. Save
- Comparative analysis of CRISPR off-target activity discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells Save
- Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells Save
- Ultra-deep sequencing reveals no evidence of oncogenic mutations or enrichment by ex vivo CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells Save
- Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Save
- Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells. Save
- Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex. Save
- Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Save
- Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination. Save
- Identification of preexisting adaptive immunity to Cas9 proteins in humans. Save
- Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. Save
- Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Save
- Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas. Save